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In this issue of Immunity, reports by Long et al. (2009) and Ruan et al. (2009) suggest that the transcription
factor NF-kB-c-Rel is an important molecular mechanism by which T cell receptor-specificity for self-anti-
gens instructs the selection of Foxp3+ regulatory T cells.The selection of a small portion of devel-
oping T cells into the regulatory T (Treg)
cell subset is a crucial step in ensuring
that the immune system remains tolerant
to self. Although T cell receptor (TCR)
recognition of self-antigens has long been
suggested to be important for this pro-
cess, the molecular mechanism by which
TCR activation leads to the expression
of Foxp3, a transcription factor required
for Treg cell stability and function, was
unclear. In this issue of Immunity, reports
by Long et al. (2009) and Ruan et al. (2009)
demonstrate that this missing link is likely
provided by NF-kB signaling via the c-Rel
transcription factor.
Initial studies of TCR transgenic models
demonstrated that thymic Treg cell devel-
opment is dependent on interactions
with cognate antigen, implying that self-
antigen recognition is crucial for Treg
cell selection. These data were further
supported by the observation that Treg
cells typically used different TCRs than
conventional Foxp3– T cells in studies of
mice with limited TCR diversity. However,
the role of TCR specificity in Treg cell
development has been controversial in
recent years, based on data suggesting
that events at the thymic double-negative
(CD4–CD8–) stage before TCR rearrange-
ment affected Treg cell development
(Pennington et al., 2006), as well as the
provision of an alternative interpretation
of TCR repertoire studies (Pacholczyk
et al., 2007). In part, this controversy per-
sisted because of the lack of transgenic
models of Treg cell development using
naturally arising Treg cell TCRs, which
was recently addressed by two indepen-
dent groups (Bautista et al., 2009; Leung
et al., 2009). The long delay in generation
of these Treg cell TCR transgenic models
was due to the fact that the selection
niche for these Treg cell TCRs were852 Immunity 31, December 18, 2009 ª2009remarkably small, such that Treg cell TCR
transgenic mice harbored an extremely
low frequency (<0.1%) of Foxp3+ thymo-
cytes, making it unclear whether this
represented TCR-driven Treg cell devel-
opment. As the clonal frequency of the
TCR transgenic cells was decreased,
the frequency of Foxp3+ cells increased
substantially. Importantly, TCRs from
non-Treg cells were unable to facilitate
Treg cell development under the same
conditions, strongly supporting the orig-
inal notion that Treg cell selection is
dependent on TCR-derived signals.
Differences in TCR usage between Treg
and conventional T cells could arise
before or after induction of Foxp3. It has
been argued that stochastic expression
of Foxp3 allows those cells to survive neg-
ative selection, thus skewing self-reactive
TCRs toward the Treg cell population (Van
Santen et al., 2004). However, no Foxp3+
cells were observed in several TCR trans-
genic lines (Bautista et al., 2009; Leung
et al., 2009), even at low clonal frequency,
suggesting that stochastic induction of
Foxp3 does not occur, at least at
readily detectable numbers. Thus, under-
standing the molecular mechanism by
which certain TCR specificities were pref-
erentially found in the Treg cell subset
would be crucial for understanding thymic
Treg cell development.
One potential pathway downstream of
TCR has been suggested to be NF-kB,
as mice deficient in upstream compo-
nents such as PKC-q, Bcl10, CARMA1,
and MALT1 had few Treg cells (Figure 1).
To carefully analyze the contribution of
this pathway for Treg cell development,
Long et al. utilized transgenic mice engi-
neered to augment or inhibit NF-kB sig-
naling (Long et al., 2009). NF-kB signaling
involves receptor-mediated activation of
the kinase IKK, which phosphorylatesElsevier Inc.cytoplasmic IkB (inhibitor of kB), resulting
in its degradation, thereby allowing the
release of bound transcription factors to
the nucleus. Therefore, NF-kB signaling
can be enhanced by a constitutively
active IKKb kinase and inhibited by a
nondegradable IkB (‘‘+’’ and ‘‘’’ in Fig-
ure 1, respectively). Here, they observed
that enhancement of NF-kB signaling
resulted in a 5-fold increase in the
frequency of Foxp3+ cells in the thymus,
and for inhibition, a 50% decrease. They
also observed that transgenic enhance-
ment of NF-kB signaling can rescue the
defect in CARMA1- and TAK1-deficient
mice, demonstrating that NF-kB, and not
other signaling proteins JNK or NFAT, is
the relevant pathway downstream of the
CARMA1-Bcl10-MALT1 complex. One
curious observation was that Foxp3+ cells
elicited directly by NF-kB signals often did
not express CD25 and were less suppres-
sive compared with normal Treg cells.
However, the Foxp3 locus in transgenic
NF-kB-induced Treg cells was appropri-
ately demethylated. Thus, although trans-
genic NF-kB-enhanced signals alone may
not mimic all facets of Treg cell develop-
ment; it is clear that NF-kB plays a crucial
role.
To address whether NF-kB itself is suf-
ficient for inducing Foxp3 without specific
TCR signals, Long et al. studied OTII and
P14 TCR transgenic mice in which those
TCRs are unable to facilitate Treg cell
development. Similar to the results with
the upstream mediators CARMA1 and
TAK1, transgenic enhancement of NF-kB
signaling was also able to bypass the
requirement for TCR self-recognition to
induce Treg cell development. In fact,
CD8+ Treg cells were even observed at
high frequency in the P14 TCR transgenic
line. These data therefore suggest that
NF-kB is a direct link between TCR
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Figure 1. Simplified Representation of
Foxp3 Induction
TCR and CD28 stimulation results in a signaling
cascade that includes the CARMA1-Bcl10-
MALT1 complex and TAK1 kinase, which leads to
activation of IKK via phopshorylation. IKK then
phosphorylates IkB, which is degraded and
releases NF-kB transcription factor c-Rel to bind
to the Foxp3 promoter. Long et al. (2009) utilize
a constitutively active form of IKKb to enhance
NF-kB signaling, or a nondegradable form of IkB,
which are indicated by a (+) or (–), respectively.
Smad and Stat5 mediators of TGF-b and common
g-chain cytokines (IL-2, IL-15, and IL-7 in this
case), respectively, are also shown.
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There are many potential mechanisms
by which NF-kB could induce Foxp3. It
could be direct by binding of NF-kB family
transcription factors to the Foxp3 locus, or
it could be indirect by affecting other
genes important for Treg cell development
such as IL-2. For example, it was recently
reported that Stat5 played an important
role in the induction of Foxp3, as trans-
genic expression of a hyperactive form of
Stat5 markedly increased the frequency
of Foxp3+ cells (Burchill et al., 2008). How-
ever, neither the expression of common
g-chain receptors, nor sensitivity to the
cytokines, was altered in with transgenic
enhancement of NF-kB signaling. These
data, therefore, argued against an indirect
role of NF-kB in Treg cell development.
To determine if NF-kB directly played
a role in the induction of Foxp3, Ruan
et al. (2009) studied mice deficient inmembers of the NF-kB family, observing
that c-Rel, and not p50 or RelB, were
required for efficient development of thy-
mic Treg cells. The presence of normal
thymocytes was unable to reverse the
inability of c-Rel- deficientcells togenerate
Treg cells in mixed bone marrow chimeras,
further supporting a direct role of c-Rel in
Foxp3 induction. Analysis of the Foxp3
promoter in vitro using luciferase assays
revealed two NF-kB binding sites, which
were confirmed using gel-shift assays.
Chromatin immunopreciptation (ChIP) and
sequential ChIP was then used to identify
the transcription factors c-Rel, p65,
NFATc2, and later, Smad and CREB at
the promoter after TCR stimulation. Thus,
these data demonstrate that TCR signaling
results in the formation of a c-Rel enhan-
ceosome in the Foxp3 promoter.
There are a couple of differences
between these reports. Long et al. suggest
that c-Rel binds as a dimer with p50 and
can also bind to a region of Foxp3 distal
to the promoter termed CNS3, whereas
Ruan et al. suggest that c-Rel dimerizes
with p65 and did not identify other binding
sites for c-Rel. This could be related to
differences in stimulation conditions or
cell types used for their analyses. None-
theless, both reports agree on a central
role for c-Rel in Foxp3 transcription.
In the context of a recently proposed
model for thymic Treg cell development
(Burchill et al., 2008; Lio and Hsieh, 2008;
Wirnsberger et al., 2009), these studies
suggest that TCR signaling via NF-kB and
c-Rel could provide an instructive signal
to open the Foxp3 locus (Figure 1). Very
strong TCRsignals would still lead to nega-
tive selection by NF-kB and other path-
ways (Long et al., 2009). Common g-chain
cytokines, such as IL-2, would then induce
high Foxp3 expression via Stat5, com-
pleting Treg cell development. TGF-b
signals may also contribute, as deficiency
in both TGF-b and IL-2 signals result in
a dramatic decrease in thymic Treg cell
frequency in adult mice compared with
either one alone (Liu et al., 2008). Future
studies will be required to address the
requirement for a second cytokine-derived
signal in the context of NF-kB-c-Rel for
Foxp3 gene regulation in the thymus.
Regardless, this model is likely to be
incomplete. Many pathways can induce
NF-kB, and many cell types can receive
Stat5 and Smad signals, yet high Foxp3
expression is primarily found on TregImmunity 31, Dcells. Additionally, it could be argued
that induction of Foxp3 via NF-kB result-
ing from proinflammatory Toll-like recep-
tor ligands or cytokines may be counter-
productive to effective immunity against
pathogens. The proposal by Long et al.
that NF-kB is a thymic sensor of inflam-
mation needs to be tested more rigor-
ously. The observed relative preservation
of Treg cell numbers after lipopolysaccha-
ride challenge could have alternative
explanations.For example, corticosteroid-
mediated apoptosis could preferentially
spare thymic Treg cells as they are more
mature than most CD4+ thymocytes.
Taken together, it is likely that additional
factors are involved in the regulation
of Foxp3. Although future studies are
required, the recognition that NF-kB-c-
Rel links TCR specificity and Foxp3
expression is important for understanding
the mechanism by which a few thymo-
cytes are instructed, based on thymic
antigen recognition, to become the regu-
lators defending against home grown
perpetrators of autoimmunity.REFERENCES
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